Pleural Effusion and an Axillary Mass in a Woman With HypertensionApril 28, 2021Metastatic Breast Cancer
Cell-free DNA improves response prediction in breast cancerApril 21, 2021Breast CancerMetastatic Breast Cancer
How has COVID-19 affected metastatic breast cancer treatment decisions?February 26, 2021Metastatic Breast Cancer
PET predicts response to endocrine therapy in ER+ breast cancerFebruary 19, 2021Breast CancerMetastatic Breast Cancer
Obesity ‘clearly’ not tied to worse survival in metastatic breast cancerFebruary 1, 2021Breast CancerMetastatic Breast Cancer
Entinostat doesn’t overcome endocrine resistance in advanced breast cancerJanuary 12, 2021Breast CancerMetastatic Breast Cancer
After 48 years, NCI aims to track breast cancer recurrencesJanuary 8, 2021Breast CancerMetastatic Breast Cancer
Margetuximab approved for HER2-positive metastatic breast cancerDecember 18, 2020Breast CancerMetastatic Breast Cancer
An all-oral option for advanced HR+, HER2– breast cancer?December 17, 2020Breast CancerMetastatic Breast Cancer
Pembro benefits in mTNBC regardless of chemo typeDecember 16, 2020Breast CancerMetastatic Breast Cancer
First-in-class ADC has benefit across mTNBC subgroupsDecember 14, 2020Breast CancerMetastatic Breast Cancer
CTCs predict overall survival in metastatic breast cancerDecember 9, 2020Breast CancerMetastatic Breast Cancer
Should CTCs guide treatment choice in HR+, HER2– breast cancer?December 3, 2020Breast CancerMetastatic Breast Cancer
Pembrolizumab approved for triple-negative breast cancerNovember 16, 2020Breast CancerMetastatic Breast Cancer
